Brendan Connell

2PUBLICATIONS
30CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (2)

|Jan 08, 2026
Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators.

Ferran Fece de la Cruz, Andreas Varkaris, Parasvi S Patel

|Jun 21, 2022
Safety of sequential immune checkpoint inhibitors after prior immune therapy.

Muhammad Awidi, Brendan Connell, Delaney Johnson

Pageof 1